Jens Wendland
Chief Medical Officer Kynexis Therapeutics
Seminars
Wednesday 16th September 2026
Modulating Oxidative Stress via KAT II Inhibition: Phase 1 Insights from KYN 5356 for Cognitive Impairment in Schizophrenia
12:15 pm
- How KYN 5356, a first in class KAT II inhibitor, targets the kynurenine pathway to address CIAS, a major unmet driver of disability in schizophrenia
- Phase 1 results demonstrating excellent safety, tolerability, and robust CNS penetration with favorable plasma and CSF pharmacokinetics
- Evidence of target engagement through dose dependent reductions in CSF kynurenic acid and EEG improvements linked to cognitive pathways
- Early signals of cognitive improvement supporting progression to Phase 2 trials in CIAS and broader precision medicine applications
